Lexaria Historical Financial Ratios
LEXXW Stock | USD 0.78 0.03 4.00% |
Lexaria Bioscience is lately reporting on over 84 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 26.35 will help investors to properly organize and evaluate Lexaria Bioscience Corp financial condition quickly.
Lexaria |
About Lexaria Financial Ratios Analysis
Lexaria Bioscience CorpFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Lexaria Bioscience investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Lexaria financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Lexaria Bioscience history.
Lexaria Bioscience Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Lexaria Bioscience Corp stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Lexaria Bioscience sales, a figure that is much harder to manipulate than other Lexaria Bioscience Corp multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ptb Ratio
Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.Book Value Per Share
The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most ratios from Lexaria Bioscience's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Lexaria Bioscience Corp current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. At this time, Lexaria Bioscience's POCF Ratio is fairly stable compared to the past year. Interest Coverage is likely to climb to 1.33 in 2024, whereas Book Value Per Share is likely to drop 0.08 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 288.38 | 282.77 | 121.44 | 26.35 | PTB Ratio | 2.19 | 2.28 | 6.03 | 54.87 |
Lexaria Bioscience fundamentals Correlations
Click cells to compare fundamentals
Lexaria Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lexaria Bioscience fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Price To Sales Ratio | 32.31 | 37.79 | 68.21 | 30.7 | 104.29 | 104.94 | |
Ptb Ratio | 4.92 | 2.06 | 2.19 | 2.28 | 6.03 | 54.87 | |
Days Sales Outstanding | 297.97 | 172.92 | 288.38 | 282.77 | 121.44 | 26.35 | |
Book Value Per Share | 0.9 | 2.97 | 1.3 | 0.41 | 0.62 | 0.0816 | |
Free Cash Flow Yield | (0.32) | (0.22) | (0.15) | (0.29) | (0.87) | 0.001992 | |
Operating Cash Flow Per Share | (0.96) | (0.91) | (0.83) | (0.89) | (0.4) | 0.0125 | |
Stock Based Compensation To Revenue | 2.82 | 2.96 | 0.57 | 2.95 | 0.75 | 1.06 | |
Capex To Depreciation | 0.3 | 0.54 | 0.93 | 1.17 | 0.8 | 0.76 | |
Pb Ratio | 4.92 | 2.06 | 2.19 | 2.28 | 6.03 | 54.87 | |
Ev To Sales | 29.35 | 22.82 | 45.64 | 25.45 | 90.59 | 106.04 | |
Free Cash Flow Per Share | (0.97) | (0.93) | (0.85) | (0.91) | (0.4) | 0.008923 | |
Roic | (1.5) | (0.26) | (0.91) | (2.15) | (0.7) | 0.1 | |
Inventory Turnover | 0.85 | 5.91 | 1.87 | (88.64) | (79.78) | (75.79) | |
Net Income Per Share | (1.45) | (0.57) | (1.24) | (1.01) | (0.47) | (0.0728) | |
Days Of Inventory On Hand | 429.25 | 61.72 | 195.19 | (4.12) | (4.74) | (4.5) | |
Payables Turnover | 2.2 | 2.93 | 2.78 | 0.14 | 0.004558 | 8.5 | |
Sales General And Administrative To Revenue | 9.28 | 6.88 | 22.41 | 13.54 | 8.3 | 1.16 | |
Average Inventory | 107.3K | 122.1K | 73.3K | (8.8K) | (7.9K) | (7.5K) | |
Research And Ddevelopement To Revenue | 1.01 | 1.75 | 7.21 | 16.21 | 5.08 | 3.67 | |
Capex To Revenue | 0.0875 | 0.11 | 0.51 | 0.75 | 0.0835 | 0.0793 | |
Cash Per Share | 0.47 | 2.68 | 1.05 | 0.22 | 0.53 | 0.00255 | |
Pocfratio | (4.67) | (6.85) | (3.57) | (1.18) | (9.76) | 358.78 | |
Capex To Operating Cash Flow | (0.0126) | (0.0199) | (0.0269) | (0.0288) | 0.29 | 0.3 | |
Pfcf Ratio | (4.61) | (6.71) | (3.48) | (1.15) | (9.76) | 502.06 | |
Days Payables Outstanding | 165.57 | 124.67 | 131.32 | 2.6K | 80.1K | 42.94 | |
Income Quality | 0.65 | 0.95 | 0.66 | 0.88 | 0.85 | (0.93) | |
Roe | (1.6) | (0.19) | (0.91) | (2.19) | (0.72) | (0.89) | |
Ev To Operating Cash Flow | (4.24) | (4.13) | (2.39) | (0.98) | (8.48) | 362.55 | |
Pe Ratio | (3.08) | (10.91) | (2.4) | (1.04) | (8.36) | (61.55) | |
Return On Tangible Assets | (1.59) | (0.19) | (0.99) | (2.54) | (0.69) | (0.52) | |
Ev To Free Cash Flow | (4.19) | (4.05) | (2.33) | (0.95) | (8.48) | 507.35 | |
Earnings Yield | (0.32) | (0.0917) | (0.42) | (0.96) | (0.12) | (0.0162) | |
Intangibles To Total Assets | 0.1 | 0.0275 | 0.0624 | 0.15 | 0.0583 | 0.0584 | |
Net Debt To E B I T D A | 0.28 | 1.94 | 0.88 | 0.19 | 1.11 | 4.12 | |
Current Ratio | 8.53 | 81.18 | 35.96 | 8.22 | 7.18 | 0.1 | |
Tangible Book Value Per Share | 0.79 | 2.89 | 1.21 | 0.34 | 0.58 | 0.0816 | |
Receivables Turnover | 1.22 | 2.11 | 1.27 | 1.29 | 3.01 | 13.85 | |
Graham Number | 5.46 | 6.23 | 6.13 | 3.23 | 2.61 | 0.37 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.